
The single-center, prospective study evaluated the safety and efficacy of the Everoshine everolimus-eluting coronary stent (EECS) in patients with coronary artery disease (CAD). Among 193 enrolled patients, the 30-day follow-up revealed a low rate of major adverse cardiac events (MACE) (1.6%) and stent thrombosis (1.0%). At the one-year follow-up, MACE occurred in 2.6% of patients, indicating the satisfactory safety and efficacy of the Everoshine EECS in CAD patients.
Like
Save
Share